Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan plus ramipril vs placebo plus ramipril for albuminuria in hypertensive high cardiovascular risk patients
2004-000022-75Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in albuminuria, hypertension (HTN) and cardiac morbidity comparing Irbesartan (Karvea) + ramipril with Placebo + ramipril (2 arms). Primary endpoint: Change in albumin excretion rate (AER) in overnight urine. Started Oct 2004; status: completed.
02
Drugs
irbesartan
03
Conditions
albuminuriahypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on 2004-000022-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000022-75.